ONCE - DAILY ORAL DIRECT FACTOR XA INHIBITOR RIVAROXABAN IN THE LONG-TERM PREVENTION OF RECURRENT SYMPTOMATIC VENOUS THROMBOEMBOLISM IN PATIENTS WITH SYMPTOMATIC DEEP-VEIN THROMBOSIS OR PULMONARY EMBOLISM. THE EINSTEIN-EXTENSION STUDY: